![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 1 of 1. This is the beginning of the thread.
Posted by lil jimi on September 9, 2016, at 0:35:58
From 'Genome' summer 2016 issue: "A Dose of Ingenuity."
"Variations in CYP2D6 can make a person either a poor metabolizer or an ultra-high metabolizer of certain opioids. Take codeine for example, the body activates codeine by converting it into morphine ..."
"Including pain meds CYP2D6 variants impact some 40 know medications..."
Possible consequences are specified for pimozide and tetrabenazine, for Tourette's and Huntington's respectively.
"Up to 10 percent of Caucasian people carry CYP2D6 variants that interfere with drug metabolism. Fewer than 1 percent of Asians carry the variants. In some African populations, carrier rates may be as high as 35 percent."
The article elaborates about a handful of other gene variants.
Physicians, especially psychiatrists are encouraged to learn about Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines.
I find the difference in variants by populations startling.
I respond to codeine and hydrocodone as stimulants. Opioids offer me very little pain relief. This is more likely due to a variant of gene
OPRM1 in me, from what I read.(We observe also that this is another episode where Free Enterprise may not be exactly free?)
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.